Harvard University Stem Cell Institute and Hong Kong National Investment starting a strong cooperation

Hong Kong National Investment and Harvard University Stem Cell Institute have a strong cooperation.

Mr. Brock Reeve, CEO of Harvard Stem Cell Research Institute, is the Chief Investment Officer of Stem Cell and Regenerative Medisun at National Investment and Medici Medical Group.

2015-05-11 China Securities Journal

On May 8, 2015, Hong Kong Medisun Regerative Medical Center and National Investment (01227.HK) announced the appointment of Mr. Brock Reeve as the chief stem cell and regenerative medicine investment officer of the two companies.

Mr. Brock Reeve is currently the Executive Director of the Harvard University Stem Cell Institute and has graduated from Yale University and Harvard Business School. Mr. Reeve is solely responsible for the strategy and operations of the Harvard Stem Cell Institute, whose overall goal is to use stem cell biology as a tool and treatment to study and treat major degenerative diseases.

As the Chief Investor of Stem Cell and Regenerative Medicine of Medisun Medical Center, Mr. Brock Reeve will organize and lead a professional investment team to actively select the latest regenerative medicine technologies in overseas markets such as Europe, the United States, and Japan and evaluate their investment value. They will also focus on and invest in the world’s leading stem cell regenerative medicine technology, and actively participate in clinical trials and product commercialization of stem cell technology invested by Medisun Medical Center in Asia.

Medisun Medical Center is the world’s most authoritative investment organization in stem cell and regenerative medicine

As the world’s most authoritative investment organization for stem cells and regenerative medicine, Medisun Medical Center has invested in stem cell treatment technologies including heart, tumor, liver, kidney, AIDS and other diseases, fully demonstrating its investment vision and courage. After working with the Mayo Medical Group in the United States, the Medisun once again joined forces with the Harvard University Stem Cell Institute.

Mr. Danny Wong is both the Chairman of the Medisun Medical Group and National Investment (01227.HK). He has devoted himself to research and investment in the field of stem cells for the past five years. The Medisun currently has more than 300 scientists , medical consultants and investment experts from all over the world. The technologies invested by the group are distributed in Europe, the United States, Japan, Hong Kong and other places, and clinical trials are carried out simultaneously.

China’s first participation in international multi-center global synchronized clinical trials

Medisun Medical Group is committed to bringing the world’s leading stem cell and regenerative medicine technologies to China. The investment in the C-cure stem cell therapy for ischemic heart failure technology, which was invented by Mayo Medical Group, has been clinically tested in Europe and the United States. It will carry out clinical trials in China’s well-known cardiovascular hospitals such as Beijing Anzhen Hospital, Fuwai Cardiovascular Hospital and Shanghai Oriental Hospital with the support of international multi-center policy, giving Chinese hospitals the opportunity to participate in the world’s most advanced stem cell technology clinic. The Medisun also actively promote the commercialization of technology worldwide in the future. Before C-Cure’s great technology and revolutionary products for heart disease were officially launched, Medisun has launched a series of cell regeneration factor products to treat a number of diseases, and the product has entered the market.

Liang Zhen ying visits Harvard University Stem Cell Research Institute and Mr. Brock Reeve to discuss the promotion of stem cell and the development of regenerative medicine industry

Under the general environment of Hong Kong’s adjustment of the whole industry, one of the important measures is to develop the stem cell and regenerative medicine industries. Looking at the huge investment in the stem cell and regeneration field of the Medisun Medical Group, it is revealed that it will inevitably set off a disruptive business model in the market.

The Hong Kong government attaches great importance to the development of stem cells. Following the cooperation with the Caroline Medical School in Sweden, Liang Zhen ying visited the Harvard University Stem Cell Research Institute on May 5 and exchanged views with its Executive Director Brock Reeve to promote the development of the stem cell industry in Hong Kong. This will undoubtedly inject a strong shot into the cooperation between Harvard University and Hong Kong in the field of regenerative medicine. It will promote the promotion of Harvard stem cells in regenerative medicine research and technology in Hong Kong and Asia.

It can be seen that Medisun Medical Group has appointed Mr. Brock Reeve take the helm of the stem cell and regenerative medicine to investment. National Investment (01227.HK), which holds a 30% stake in Medisun Medical Group, is investing in regenerative medicine and the field of stem cells. Mr. Brock Reeve will lead the Medisun Medical Group to become a professional stem cell investment team with global leadership.

The value of the stem cell and regenerative medicine industry under the capital market in China and Hong Kong is immeasurable.

With the upcoming clinical management of stem cells, the development of China’s stem cell and regenerative medicine industry will be unstoppable. Shanghai-Hong Kong Stock Connect and the upcoming Shenzhen-Hong Kong Stock Connect have apparently injected huge sums of money into Hong Kong stocks. The stocks of companies related to the stem cell industry have risen very well, but they are far from satisfactory and far from the technology held by Medisun Medical Center. National Investment (01227.HK), as a shareholder of Medisun Medical Group, is full of confidence in the development of the Group.

Medisun Investment Holdings’ Cardio Biotech plans to enter the US capital market.

Medisun Investment Holdings’ C-cure Stem Cell Therapy for Ischemic Heart Failure has exceeded the number of patients enrolled by the European Food and Drug Administration (EMA) in the Phase III clinical trial in Europe and has been approved by the US Food and Drug Administration (FDA). Enter the third phase of clinical. Cardio, the investment holding company of Medisun, also successfully obtained a new round of financing of 32 million euros in February this year. Its financing quota was oversubscribed and snapped up by European and American institutional investors. Cardio is planning to be listed on the NASDAQ in the United States from the end of May to the beginning of June this year (listed in Belgium and France in 2013), and the large-scale financing plan of Cardio further indicates that the spring of stem cells has really come.

After many years of favor and investment in the field of stem cells and regenerative medicine, and the huge capital investment plan, the Medisun’ next step will be the focus of the market. The capital market’s confidence in its shareholder, National Investment (01227.HK), is already evident in the expectation of its future development.According to analysts, Medisun has planned to launch an overall listing financing plan in Hong Kong in the near future. We believe that Medisun, as a recognized leader in the global stem cell and regenerative medicine field, will surely launch an incredible wave of development in this field.

The News Picture:

P1:

Mr. Brock Reeve is both the chairman of Medisun medical group and National Investment (01227.HK) and a close friend of Mr. Danny Wong during his stay in the United States.They share the same confidence and enthusiasm for stem cell and regenerative medicine.

P2:

Hong Kong Chief Executive Liang Zhen ying visited the Harvard University Stem Cell Institute and exchanged views with the Executive Director, Mr. Brock Reeve, on the development of the stem cell and regenerative medicine industries.

Source: http://www.medisun.hk/

Brock Reeve is the younger brother of the famous American actor Christopher Reeve. Christopher Reeve (September 25, 1952 – October 10, 2004), a New Yorker, famous movie actor, film director, writer, was play in Superman (Kal-El/Clark Kent). He graduated from Cornell University in 1974 with a Bachelor of Arts degree and then entered the Juilliard School in New York. He is also a good friend with another famous actor Robin Williams. In 1978, he starred in the sci-fi film “Superman” for the first time and became a hit. In 1995, an accident occurred during an equestrian competition. The spine was seriously injured and his body was paralyzed. Since then, he has devoted himself to social welfare undertakings and to promote stem cell research. He often holds tour lectures. On October 9, 2004, he died for the myocardial infarction at the age of 52.

Hong Kong National Investment and Harvard University Stem Cell Institute starting a strong partnership

Hong Kong National Investment and Harvard University Stem Cell Institute have a strong cooperation.

Mr. Brock Reeve, CEO of Harvard Stem Cell Research Institute, is the Chief Investment Officer of Stem Cell and Regenerative Medisun at National Investment and Medici Medical Group.

2015-05-11 China Securities Journal

On May 8, 2015, Hong Kong Medisun Regerative Medical Center and National Investment (01227.HK) announced the appointment of Mr. Brock Reeve as the chief stem cell and regenerative medicine investment officer of the two companies.

Mr. Brock Reeve is currently the Executive Director of the Harvard University Stem Cell Institute and has graduated from Yale University and Harvard Business School. Mr. Reeve is solely responsible for the strategy and operations of the Harvard Stem Cell Institute, whose overall goal is to use stem cell biology as a tool and treatment to study and treat major degenerative diseases.

As the Chief Investor of Stem Cell and Regenerative Medicine of Medisun Medical Center, Mr. Brock Reeve will organize and lead a professional investment team to actively select the latest regenerative medicine technologies in overseas markets such as Europe, the United States, and Japan and evaluate their investment value. They will also focus on and invest in the world’s leading stem cell regenerative medicine technology, and actively participate in clinical trials and product commercialization of stem cell technology invested by Medisun Medical Center in Asia.

Medisun Medical Center is the world’s most authoritative investment organization in stem cell and regenerative medicine

As the world’s most authoritative investment organization for stem cells and regenerative medicine, Medisun Medical Center has invested in stem cell treatment technologies including heart, tumor, liver, kidney, AIDS and other diseases, fully demonstrating its investment vision and courage. After working with the Mayo Medical Group in the United States, the Medisun once again joined forces with the Harvard University Stem Cell Institute.

Mr. Danny Wong is both the Chairman of the Medisun Medical Group and National Investment (01227.HK). He has devoted himself to research and investment in the field of stem cells for the past five years. The Medisun currently has more than 300 scientists , medical consultants and investment experts from all over the world. The technologies invested by the group are distributed in Europe, the United States, Japan, Hong Kong and other places, and clinical trials are carried out simultaneously.

China’s first participation in international multi-center global synchronized clinical trials

Medisun Medical Group is committed to bringing the world’s leading stem cell and regenerative medicine technologies to China. The investment in the C-cure stem cell therapy for ischemic heart failure technology, which was invented by Mayo Medical Group, has been clinically tested in Europe and the United States. It will carry out clinical trials in China’s well-known cardiovascular hospitals such as Beijing Anzhen Hospital, Fuwai Cardiovascular Hospital and Shanghai Oriental Hospital with the support of international multi-center policy, giving Chinese hospitals the opportunity to participate in the world’s most advanced stem cell technology clinic. The Medisun also actively promote the commercialization of technology worldwide in the future. Before C-Cure’s great technology and revolutionary products for heart disease were officially launched, Medisun has launched a series of cell regeneration factor products to treat a number of diseases, and the product has entered the market.

Liang Zhen ying visits Harvard University Stem Cell Research Institute and Mr. Brock Reeve to discuss the promotion of stem cell and the development of regenerative medicine industry

Under the general environment of Hong Kong’s adjustment of the whole industry, one of the important measures is to develop the stem cell and regenerative medicine industries. Looking at the huge investment in the stem cell and regeneration field of the Medisun Medical Group, it is revealed that it will inevitably set off a disruptive business model in the market.

The Hong Kong government attaches great importance to the development of stem cells. Following the cooperation with the Caroline Medical School in Sweden, Liang Zhen ying visited the Harvard University Stem Cell Research Institute on May 5 and exchanged views with its Executive Director Brock Reeve to promote the development of the stem cell industry in Hong Kong. This will undoubtedly inject a strong shot into the cooperation between Harvard University and Hong Kong in the field of regenerative medicine. It will promote the promotion of Harvard stem cells in regenerative medicine research and technology in Hong Kong and Asia.

It can be seen that Medisun Medical Group has appointed Mr. Brock Reeve take the helm of the stem cell and regenerative medicine to investment. National Investment (01227.HK), which holds a 30% stake in Medisun Medical Group, is investing in regenerative medicine and the field of stem cells. Mr. Brock Reeve will lead the Medisun Medical Group to become a professional stem cell investment team with global leadership.

The value of the stem cell and regenerative medicine industry under the capital market in China and Hong Kong is immeasurable.

With the upcoming clinical management of stem cells, the development of China’s stem cell and regenerative medicine industry will be unstoppable. Shanghai-Hong Kong Stock Connect and the upcoming Shenzhen-Hong Kong Stock Connect have apparently injected huge sums of money into Hong Kong stocks. The stocks of companies related to the stem cell industry have risen very well, but they are far from satisfactory and far from the technology held by Medisun Medical Center. National Investment (01227.HK), as a shareholder of Medisun Medical Group, is full of confidence in the development of the Group.

Medisun Investment Holdings’ Cardio Biotech plans to enter the US capital market.

Medisun Investment Holdings’ C-cure Stem Cell Therapy for Ischemic Heart Failure has exceeded the number of patients enrolled by the European Food and Drug Administration (EMA) in the Phase III clinical trial in Europe and has been approved by the US Food and Drug Administration (FDA). Enter the third phase of clinical. Cardio, the investment holding company of Medisun, also successfully obtained a new round of financing of 32 million euros in February this year. Its financing quota was oversubscribed and snapped up by European and American institutional investors. Cardio is planning to be listed on the NASDAQ in the United States from the end of May to the beginning of June this year (listed in Belgium and France in 2013), and the large-scale financing plan of Cardio further indicates that the spring of stem cells has really come.

After many years of favor and investment in the field of stem cells and regenerative medicine, and the huge capital investment plan, the Medisun’ next step will be the focus of the market. The capital market’s confidence in its shareholder, National Investment (01227.HK), is already evident in the expectation of its future development.According to analysts, Medisun has planned to launch an overall listing financing plan in Hong Kong in the near future. We believe that Medisun, as a recognized leader in the global stem cell and regenerative medicine field, will surely launch an incredible wave of development in this field.

The News Picture:

P1:

Mr. Brock Reeve is both the chairman of Medisun medical group and National Investment (01227.HK) and a close friend of Mr. Danny Wong during his stay in the United States.They share the same confidence and enthusiasm for stem cell and regenerative medicine.

P2:

Hong Kong Chief Executive Liang Zhen ying visited the Harvard University Stem Cell Institute and exchanged views with the Executive Director, Mr. Brock Reeve, on the development of the stem cell and regenerative medicine industries.

Source: http://www.medisun.hk/

Brock Reeve is the younger brother of the famous American actor Christopher Reeve. Christopher Reeve (September 25, 1952 – October 10, 2004), a New Yorker, famous movie actor, film director, writer, was play in Superman (Kal-El/Clark Kent). He graduated from Cornell University in 1974 with a Bachelor of Arts degree and then entered the Juilliard School in New York. He is also a good friend with another famous actor Robin Williams. In 1978, he starred in the sci-fi film “Superman” for the first time and became a hit. In 1995, an accident occurred during an equestrian competition. The spine was seriously injured and his body was paralyzed. Since then, he has devoted himself to social welfare undertakings and to promote stem cell research. He often holds tour lectures. On October 9, 2004, he died for the myocardial infarction at the age of 52.

Élodie D’Ambrosio : Une Jeune Talent Prometteuse dans le Monde de l’Animation

Élodie D’Ambrosio : Une Jeune Talent Prometteuse dans le Monde de l’Animation

En 2015, l’animation continue de captiver les audiences à travers le monde, et parmi les talents émergents de cette industrie dynamique, Élodie D’Ambrosio se distingue comme une créatrice innovante avec une vision artistique unique. Bien que jeune, son travail commence à attirer l’attention des professionnels et des passionnés d’animation, signalant le début d’une carrière prometteuse.

Une Formation Solide

Élodie D’Ambrosio a toujours été fascinée par le monde du dessin et du cinéma d’animation. Dès son plus jeune âge, elle démontre un talent précoce pour le dessin, ce qui la pousse à poursuivre des études en design graphique. En 2010, elle complète son parcours à l’École des Gobelins, une institution renommée pour ses programmes en animation. Cette formation rigoureuse lui permet d’acquérir les compétences nécessaires pour se faire un nom dans l’industrie.

Un Style Visuel Distinctif

Ce qui distingue le travail d’Élodie D’Ambrosio est son style visuel unique. Influencée par les classiques de l’animation française et internationale, elle développe une approche personnelle qui marie la fluidité des animations traditionnelles avec les techniques numériques modernes. Sa capacité à créer des personnages expressifs et des environnements visuellement captivants est déjà perceptible dans ses premières œuvres, attirant l’attention pour leur originalité et leur sensibilité artistique.

Premiers Projets et Récompenses

Élodie D’Ambrosio se fait connaître pour ses premiers courts-métrages qui commencent à être présentés dans des festivals locaux et internationaux. Son court-métrage “Éclats de Rêves”, qui explore les thèmes du rêve et de la réalité à travers une animation délicate et imaginative, reçoit des critiques positives pour son innovation visuelle et sa narration émotive. Bien que ce soit le début de sa carrière, ses projets montrent déjà une maîtrise impressionnante de l’animation et une capacité à captiver l’audience.

Une Présence Grandissante

En plus de ses projets personnels, Élodie commence à travailler en tant qu’animatrice dans des studios renommés, où elle contribue à divers projets, allant des publicités animées aux productions pour enfants. Sa capacité à collaborer avec des équipes diverses et à s’adapter à différents styles montre son professionnalisme et son potentiel dans le domaine. Les premiers signes de son influence croissante dans l’industrie deviennent apparents, faisant d’elle une créatrice à suivre de près.

Engagement envers l’Éducation

L’engagement d’Élodie D’Ambrosio envers l’éducation et la promotion de l’animation est également notable. Elle participe à des ateliers pour jeunes créateurs et donne des conférences sur l’animation, partageant son expertise et sa passion avec la prochaine génération de talents. Cet engagement démontre non seulement sa volonté de contribuer à l’évolution du domaine, mais aussi son désir de rendre l’animation accessible à un public plus large.

Perspectives d’Avenir

Alors que 2015 progresse, Élodie D’Ambrosio est bien positionnée pour continuer à développer son influence dans le monde de l’animation. Avec des projets en cours et une vision artistique en constante évolution, elle est sur le point de jouer un rôle significatif dans l’avenir de l’industrie. Les amateurs d’animation et les professionnels du secteur attendent avec impatience de voir comment elle continuera à repousser les limites de l’art et de la narration animée.

En résumé, Élodie D’Ambrosio est une jeune talentueuse dont le travail et la passion pour l’animation commencent à faire des vagues en 2015. Sa créativité, son engagement et son style distinctif font d’elle une figure montante à surveiller dans les années à venir.

Mayo and Medisun have joined forces to enter the Chinese medical market

Medisun Medical Group 2015-01-26,

Taking the first year of China’s medical reform in 2015 as an opportunity, Mayo and Medisun have joined forces to enter the Chinese medical market in large numbers. It can be said that it is at the right time. Dr. Cao Shengyu, President of Medici Medical Group, former General Manager of Hong Kong Queen Elizabeth Hospital and General Manager of Kowloon China Network and managing the five public hospitals, said: “Based on our experience in investing in hospitals in Hong Kong and China over the past 20 years, and in the new environment of China’s medical system reform, Medisun is confident to introduce Mayo’s advanced medical service system to China and benefit patients. According to the GATT and the planning process of a number of specific work agreements, we will gradually provide Mayo’s medical services from Hong Kong to Beijing and Shanghai.

The establishment of the Mayo affiliated hospital system have truly brought Mayo’s world-class medical care to Chinese patients. Dr. Cao was the President of the China Hospital Society HCA (Hospital Corporation of America), responsible for establishing sino-American joint venture hospital in China.

On January 22, 2015, at the strategic cooperation ceremony between Mayo and Medisun, Mayo President Jeffrey Burton led the Mayo executives to accept the Chinese Song Dynasty Tiansheng Acupuncture Copper Man presented by Chairman Madison

Dr. Zhang Yuanxin, senior vice president of Medisun Medical Group and senior bio-industry analyst on Wall Street in the United States, joined Medisun in recognition of Medisun’s expectations for regenerative medicine and China’s healthcare reform. He said, “The cooperation between Mayo and Medisun began with Medisun’s investment in cutting-edge technologies in regenerative medicine.

The two sides have reached a high consensus on the concept of developing medical services in China. Mayo values Medisun’s strategic position in connecting Hong Kong and connecting things. And Medisun’s existing advanced medical facilities and experienced management team, and reached a long-term cooperation agreement with Medisun. This understanding and understanding laid a solid foundation for the cooperation between the two, and the real benefit is the Chinese patients.

Source: http://www.medisun.hk/

Medisun is confident to introduce Mayo’s advanced medical service system to China

Medisun Medical Group 2015-01-26,

Taking the first year of China’s medical reform in 2015 as an opportunity, Mayo and Medisun have joined forces to enter the Chinese medical market in large numbers. It can be said that it is at the right time. Dr. Cao Shengyu, President of Medici Medical Group, former General Manager of Hong Kong Queen Elizabeth Hospital and General Manager of Kowloon China Network and managing the five public hospitals, said: “Based on our experience in investing in hospitals in Hong Kong and China over the past 20 years, and in the new environment of China’s medical system reform, Medisun is confident to introduce Mayo’s advanced medical service system to China and benefit patients. According to the GATT and the planning process of a number of specific work agreements, we will gradually provide Mayo’s medical services from Hong Kong to Beijing and Shanghai.

The establishment of the Mayo affiliated hospital system have truly brought Mayo’s world-class medical care to Chinese patients. Dr. Cao was the President of the China Hospital Society HCA (Hospital Corporation of America), responsible for establishing sino-American joint venture hospital in China.

On January 22, 2015, at the strategic cooperation ceremony between Mayo and Medisun, Mayo President Jeffrey Burton led the Mayo executives to accept the Chinese Song Dynasty Tiansheng Acupuncture Copper Man presented by Chairman Madison

Dr. Zhang Yuanxin, senior vice president of Medisun Medical Group and senior bio-industry analyst on Wall Street in the United States, joined Medisun in recognition of Medisun’s expectations for regenerative medicine and China’s healthcare reform. He said, “The cooperation between Mayo and Medisun began with Medisun’s investment in cutting-edge technologies in regenerative medicine.

The two sides have reached a high consensus on the concept of developing medical services in China. Mayo values Medisun’s strategic position in connecting Hong Kong and connecting things. And Medisun’s existing advanced medical facilities and experienced management team, and reached a long-term cooperation agreement with Medisun. This understanding and understanding laid a solid foundation for the cooperation between the two, and the real benefit is the Chinese patients.

Source: http://www.medisun.hk/

Heart failure patients helped to regain health by Stem Cell Therapy

The International Forum on Heart Failure and Stem Cell Therapies Focus on C-Cure Technology and Launch Ceremony of Phase III Multisite Clinical Trial in China was held jointly by six organizations including Experts Committee of China Council for Medicine International Promotion, National Stem Cell and Regenerative Medicine Industrial Technology Innovation Strategic Alliance, etc on August 25th in Shanghai. The reporter was informed from the forum that the C-Cure technology for the treatment of heart failure through stem cells will make the heart failure patients who are lack of effective treatment regain health and rebirth.

Junbo Ge, Academician from the Chinese Academy of Sciences and Deputy President of Tongji University, has introduced the current situation of heart failure worldwide on the forum, that is, the number of patients worldwide reaches 117 million, among which there are 29.971 million patients in China, accounting for 25.6% of the total. At present, the traditional therapy of end-stage heart failure requires heart transplantation, which not only arouses problems such as too less donors, long waiting time, strong rejection reaction, etc, but also brings huge economic burden to the family or even the society. Academician Ge also says that the scientists are still making unremitting efforts to promote the application of stem cell technology on Chinese people suitably and safely. He also hopes that more administrative departments will support this technology and he believes the future will definitely be the biomedical era.

Dr Andre Terzic from the Center for Regenerative Medicine of the US Mayo Clinic and the experts from the Cardiovascular Center of Belgian Aalst Hospital have introduced the cardiac repair revolution of stem cell technology——C-cure technology and C-CathEZ Catheter on the forum. The C-Cure technology involves aspiration of the patient’s bone marrow and isolation of the mesenchymal stem cell fraction. A unique and proprietary “cardiopoietic cocktail” of proteins is used to differentiate the patient’s mesenchymal stem cells into cardiac progenitor cells, or so called “cardiopoietic cells”. The heart specific stem cells are expanded in vitro and then implanted into the diseased and damaged area of the heart using the C-Cathez delivery device. These implanted cardiac stem cells regenerate and heal the heart that has been injured by myocardial infarction, or heart attack.

C-CathEZ is the world’s most advanced proprietary catheter used for delivery of stem cells to the heart. It is capable of accurately delivering diagnostic and therapeutic agents to the damaged myocardium through a minimally invasive procedure. C-CathEZ navigates to the left ventricle through the aortic arch, and its curved and porous needle stays anchored to the ventricular wall, moving in sync with the ventricular wall motion once it reached the myocardium. The porous needle can also be repositioned for injections of cells into different areas. C-CathEZ enables the injection and distribution of stem cells evenly into the damaged myocardium, resulting in a higher portion of retention of cells. The C-Cure technology and the catheter C-CathEZ have been nominated as finalists for two 2014 European Mediscience Awards, the “Breakthrough Award” and the “Best Technology Award”.

Medisun has established collaborations with the Mayo Clinic, a renowned medical group in the United States, and the two have co-invested in Cardio3 BioSciences, the owner of C-Cure technology and catheter C-CathEZ. At present, C-Cure has been authorized to conduct the Phase III clinical trial in the US and European Union, and the product could potentially be launched globally in 2016. Moreover, the technology of catheter C-CathEZ has obtained authentication and licensing from the EU in April, 2012.

In order to make the stem cell therapy be available to more Chinese heart failure patients, Mesisun Holdings Limited will establish 8 to 10 international multisite clinical bases in Shanghai, Beijing and Guangzhou to carry out the Phase III clinical trial of C-Cure technology in Mainland China. The launch ceremony of developing Phase III clinical trial by the cooperation of Cardio3 and Shanghai East Hospital has been held on the forum. Before that, Medisun Holdings Limited and Beijing Anzhen Hospital has formally launched the cooperation of Phase III clinical trial of C-Cure technology.

Zhongmin Liu, President of the East Hospital of Tongji University says, “The clinical application of stem cell is the dream of a number of clinical doctors and the experts from the stem cell field. With the gradual improvement of the isolation, culture and expansion technology of stem cells as well as the interventional methods for heart failure patients, the clinical application is promising. The East Hospital is looking for a biological cell therapy with more effectiveness and better life quality for the patients, which is able to avoid and delay the heart transplantation, that is, the application of stem cells in the heart failure treatment. Before the stem cell therapy, the heart failure patients rely on the heart transplantation ultimately. However, the time to wait for the heart donor is long, and the patient has to be hospitalized repeatedly, which costs money and makes the patient painful. With this cell technology, combining with technology of minimally invasive catheter, the result of HF treatment may be identified whenever or wherever without spending too much money. It can avoid the patients to be hospitalized repeatedly and can also reduce expenditure, which brings better life for the patients. This cell therapy brings effects that the traditional drug treatment can’t give not only for HF patients, but also for patients with diabetes, stroke, osteoarthritis, etc in the future. Therefore, the cell treatment including stem cell treatment will be the pillar industry which will be focused on to develop not only in China, but also in developed countries such as the United States, and it will certainly lead the new revolution in medical industry.

In addition, the Stem Cell Clinical Trial Management Approach will be issued in the second half of this year. We can believe that the support of relevant departments in China will certainly promote the regenerative medicine of stem cell to develop rapidly and normatively for the benefit of Chinese people.

Notes:

Medisun Holdings Limited: Medisun plans to invest in stem cell regenerative technology and products worldwide, focusing on cardiovascular diseases and other serious diseases, including cancer (leukemia, malignant lymphoma, etc.), lung disease, liver disease, kidney disease, diabetes, autoimmune disease, nerve system disease, stroke and spinal cord injury. Medisun is committed to uncovering the power of regenerative technology in treating human diseases and promoting it as the mainstay of future medicine.

Mayo Clinic: Headquartered in Rochester, Minnesota, USA, Mayo Clinic marks 150 years of service to patients in 2014. As a medical group with integrated treatment and care, medical school instruction and scientific research, Mayo is highly regarded by the international medical community and has been at or near the top of the U.S News & World Report list of “Best Hospitals” for more than 20 years. For more than a century, Mayo Clinic has been a leader in the research and development of new therapies, innovation in hospital maganement and next generation telemedicine, and it is sometimes referred as the “Supreme Court” of medicine. Today, Mayo Clinic has branches in Florida and Arizona, its own medical school and dozens of clinics in the surrounding states. It employs more than 3,800 physicians and scientists ans 50,900 allied health staff, with an annual revenue of nearly US$ 10 billion.

Affiliated companies established by Medisun in Asia and China

Cardio3 BioSciences Aisa Holdings Limited will be sponsoring the Phase III clinical development and commercialization of C-Cure for ischemic heart failure and other stem cell-based regenerative products. The company plans to enter the Japanese market with an expected launch of a clinical trial in 2015, followed by introduction into markets including India, Indonesia, etc. where the population is over 20 million.

Cardio3 BioSciences (China) Co., Ltd will be sponsoring the Phase III clinical development and commercialization of C-Cure in China.

Source : http://www.medisun.hk/

Cardio3 BioSciences teams up with Medisun International

Cardio3 BioSciences teams up with Medisun International to create Cardio3 BioSciences Asia Holdings Ltd, a Joint Venture aimed at conducting pivotal clinical programs in Greater China

• The minimum of 20M€ funding of the Joint Venture over the next three years is secured by local financial investors led by Hong Kong based Medisun International Ltd.
• The clinical program aims to lead to the commercialization of C-Cure® in the People’s Republic of China, Hong Kong and Taiwan.
• Medisun will also bring local regulatory, clinical and market access knowledge, while Cardio3 BioSciences will bring clinical and operational knowhow and expertise.
• With this additional clinical program in Asia, Cardio3 BioSciences will have access to the third largest pharmaceutical market in the world.
• The quality standards of the Asian operations will be managed by Cardio3 BioSciences, with the same rigor as the European and American operations.

Mont-Saint-Guibert, Belgium, 16 JUNE 2014 – Cardio3 BioSciences SA (C3BS) (Euronext Brussels and Paris : CARD), leader in the discovery and development of advanced regenerative therapies for heart disease, today announces it has entered into an agreement with Medisun International Limited, a financial investor based in Hong Kong aiming to build a life science portfolio, for the purpose of creating a joint venture to conduct Phase III clinical trials in Greater China (the People’s Republic of China, Hong Kong and Taiwan) potentially leading to the commercialization of C-Cure® in these territories. Medisun International Limited is also a shareholder of Cardio3 following a capital increase, the first phase of which became effective today.

The Joint Venture, named Cardio3 BioSciences Asia Holdings Ltd, will be created with the purpose to conduct pivotal clinical trials in Greater China, ie the People’s Republic of China, Hong Kong and Taiwan. Cardio3 BioSciences will bring to the Joint Venture the required IP rights to conduct a clinical trial in those geographies, the use of its C-Cure® manufacturing capabilities based in Mont-Saint-Guibert (Belgium) that will produce the clinical lots for the Phase III program, and its clinical and operational knowhow and expertise. Medisun will bring to the joint venture the funding required for the execution of the clinical trials, with a minimum committed of 20M€ over a three year period, as well as local knowledge of the clinical and regulatory environment.

Cardio 3 BioSciences’s ownership in the Joint Venture will be 40%, to be reduced to 30% when clinical trials are running in the three geographies.
A successful outcome of the Phase III clinical program in those geographies would trigger the right for the joint venture company to commercialize C-Cure® in those territories with royalties ranging between 20 and 30% of net sales depending on total revenue of the Joint Venture.

The obligations under the joint venture agreement are still subject to the completion of the second tranche (for 12.5M€) of a 25 M€ investment in Cardio 3 BioSciences by Medisun on 30 June 2014.

With clinical programs ongoing in Europe and Israel, and soon in the USA and Greater China (People’s Republic of China, Hong Kong and Taiwan), Cardio3 BioSciences confirms its leadership in the cardiac regenerative field with its global presence.

Dr Christian Homsy, CEO of Cardio3 BioSciences, said: “We are delighted to have the opportunity to access the world’s third largest pharmaceutical market at limited costs to Cardio3. In cooperation with a reputable local partner, we look forward to soon initiating one or more pivotal trials that would lead us towards commercialization in the world’s fastest growing economy. We are also delighted that both partners are committed to the most rigorous standards of pharmaceutical practices and scientific integrity.”

Mr Michel Lussier, Chairman of Cardio3 BioSciences, added: “With this presence in Greater China, we are very proud to become the first global player in the field of cardiac regenerative medicines, aiming to commercialize our leading edge cell therapy to patients all across the globe.”

Mr Danny Wong, Chairman of Medisun International Holdings Ltd., added: “I am very proud that we are able to pioneer the clinical development of this exciting technology in China and potentially later on in Asia. Our ultimate goal is to deliver this live-saving treatment to countless patients with heart problems.

We are passionate about this project and I am certain that our involvement with Cardio3 as a leader in this field, combined with our local knowledge of the regulatory, healthcare and market access capabilities and expertise, will bring success to all the parties involved.” Read more details on http://www.medisun.hk/.